Pertussis Vaccine Adsorbed

Summary

Pertussis Vaccine Adsorbed (CHEMBL2109220) is a phase-3 clinical-stage vaccine component; indicated across 4 conditions including dengue hemorrhagic fever and dengue disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Vaccine component
• Indications: 4 conditions

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109220
Name	Pertussis Vaccine Adsorbed
Type	Vaccine component
Max phase	3

Also known as: Pertussis vaccine adsorbed, PERTUSSIS VACCINE ADSORBED

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Dengue hemorrhagic fever	3	MONDO:0005358	EFO:0004227
dengue disease	3	MONDO:0005502	EFO:0005547
B-cell chronic lymphocytic leukemia	2	MONDO:0004948	EFO:0000095
HIV infectious disease	1	MONDO:0005109	EFO:0000764

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).